Alliance Global Partners analyst Aaron Grey lowered the firm’s price target on Organigram (OGI) to C$3 from C$4.25 and keeps a Buy rating on the shares. The company’s Q1 results were below estimates as seasonality was worse than anticipated, the analyst tells investors in a research note. The firm still sees Organigram as positioned to drive profitable sales growth in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGI:
- Options Volatility and Implied Earnings Moves Today, February 11, 2025
- Organigram Holdings’ Strong Q1 Growth and Strategic Expansion
- Organigram reports Q1 revenue C$42.7M vs. C$36.5M last year
- Organigram Holdings to Announce Q1 Fiscal 2025 Results
- Biotech Alert: Searches spiking for these stocks today